Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Blood pressure measurement, COVID-19, Hypertension, Illness
Clinical narrative: Asthma; Sinusitis; Hypertension; Vaccination failure; COVID-19; Unspecified illness; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Unspecified illness), VACCINATION FAILURE (Vaccination failure), COVID-19 (COVID-19), ASTHMA (Asthma) and SINUSITIS (Sinusitis) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for Prophylactic vaccination: influenza (influenza vaccine for flu). Past adverse reactions to the above products included Ill feeling with influenza. Concurrent medical conditions included Penicillin allergy, Drug allergy (tetracycline and sulfa), Shellfish allergy and Asthma.    On 12-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced ILLNESS (Unspecified illness). On 06-Feb-2022, the patient experienced VACCINATION FAILURE (Vaccination failure) and COVID-19 (COVID-19). On an unknown date, the patient experienced ASTHMA (Asthma), SINUSITIS (Sinusitis) and HYPERTENSION (Hypertension). On 06-Feb-2022, VACCINATION FAILURE (Vaccination failure) had resolved. At the time of the report, ILLNESS (Unspecified illness) and SINUSITIS (Sinusitis) outcome was unknown and COVID-19 (COVID-19), ASTHMA (Asthma) and HYPERTENSION (Hypertension) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: 170/90 (High) 170/90 mmHg..         No concomitant medication information was provided.  No treatment medication was provided.  Company comment: This is a spontaneous case concerning a 60-year-old female  patient with asthma, who experienced the non-serious unexpected event of COVID-19 (AESI), more than 8 months after the administration of second dose of mRNA-1273 vaccine. Patient had COVID-19 rapid test and PCR with positive results. Patient did not specify any symptoms but reported that she not had fever. Vaccination failure was also included  as an event. Seven months after primary vaccination with mRNA-1273, patient received a dose of COVID-19 vaccine ad26.cov2.s Janssen.  The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-509055 (Patient Link). Sender's Comments: Company comment: This is a spontaneous case concerning a 60-year-old female  patient with asthma, who experienced the non-serious unexpected event of COVID-19 (AESI), more than 8 months after the administration of second dose of mRNA-1273 vaccine. Patient had COVID-19 rapid test and PCR with positive results. Patient did not specify any symptoms but reported that she not had fever. Vaccination failure was also included  as an event. Seven months after primary vaccination with mRNA-1273, patient received a dose of COVID-19 vaccine ad26.cov2.s Janssen.  The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.